HIV Antivirals Market is expected to reach US$ 47.0 Billion by 2032: Advancements and Future Outlook for Treating HIV/AIDS | Says FMI

The HIV Antivirals Market refers to the pharmaceutical sector dedicated to the development, production, and sale of medications used for the treatment of HIV (Human Immunodeficiency Virus) infection. Antiretroviral therapy (ART) is the primary approach for managing HIV, and it involves the use of a combination of antiviral drugs to suppress the replication of the virus and slow down the progression of the disease.

The market for HIV antivirals is expected to reach a value of $30.6 billion by 2022. By the end of 2032, the market for HIV antivirals is projected to be worth US$ 47.0 billion, with a 4.4% CAGR in sales revenue between 2022 and 2032. Fixed-dose combos (FDCs) would control more than 83% of the HIV antivirals market in 2021, according to a recent projection.

The need for HIV antivirals is being driven by the rising prevalence of HIV worldwide. The Joint United Nations Programme on HIV/AIDS (UNAIDS) estimates that there will be about 37.7 million HIV-positive people in the globe by 2020.

Download our Sample Report now and embark on a journey towards innovation and prosperity @ https://www.futuremarketinsights.com/reports/sample/rep-gb-15095

Additionally, if the prevalence of unprotected sex and the use of contaminated needles or syringes increases, so will the demand for HIV antivirals. In the United States, 38% of respondents to the 2019 National Youth Risk Behaviour Survey by the Centres for Disease Control and Prevention (CDC) reported having sexual contact, while 9% reported having four or more partners.

As a result, major players are producing generic anti-HIV drugs at a low cost to take advantage of the growing demand. For instance, generic versions of Lamivudine, Abacavir, and Efavirenz are offered in the United States at lower costs than their branded counterparts. This is anticipated to create a lucrative opportunity for manufacturers of generic HIV antivirals to offer affordable medical services to low- and middle-income nations.

Key Takeaways from Market Study

• Because of their ability to increase adherence to an HIV treatment regimen, fixed-dose combinations (FDCs) owned more than 83.2% of the market value in 2021.
• Hospital pharmacies are the dominant sales channel for HIV antivirals, accounting for over 53.4% of the market in 2021, and are expected to increase at a CAGR of 4.5% over the next decade.
• In 2021, the United States dominated the North American HIV antivirals market, with a total market share of around 96.8%.
• Because of the increasing number of HIV patients in the country, India is likely to lead the growth in the South Asian market.

“With increasing awareness among the people about HIV causes and symptoms, the HIV antivirals market is set witness positive growth during the forecast period. Hence, key players are developing anti-HIC drugs vaccines to increase their revenue,” says an analyst of Future Market Insights.

For any Queries Related with the Report, Ask an Analyst@ https://www.futuremarketinsights.com/ask-question/rep-gb-15095

Market Competition

Key Players:

• Merck & Co., Inc.
• Johnson & Johnson
• Genetech, Inc.
• Teva Pharmaceutical Industries Ltd.
• AbbVie
• Cipla
• Pfizer Inc.
• Mylan N.V.
• Others

Market players are expanding the business through collaborations, and increasing involvement in clinical trials as the key strategy with instances of key companies, such as Merck and Gilead, in order to improve their reach in the market and compete with other key players in forthcoming years. For instance:

• Merck reported positive results from two pivotal Phase 3 trials of the experimental, once-daily oral fixed-dose combination tablet of doravirine/islatravir (DOR/ISL) in adults with HIV-1 infection in October 2021.
• Gilead announced in March 2021, in collaboration with Merck, the development and marketing of long-acting, experimental therapy combinations of Lenacapavir and Islatravir in HIV.

Customize Your Knowledge: Unlock Targeted Insights to Drive Growth in the HIV Antivirals Market @ https://www.futuremarketinsights.com/customization-available/rep-gb-15095

Key Market Segments Covered in HIV Antivirals Market Research

By Product:

• Fixed Dose Combinations (FDCs)
• Integrase Strand Transfer Inhibitors (INSTIs)
• Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
• Entry Inhibitors – CCR5 co-receptor antagonist
• Protease Inhibitors (PIs)
• Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
• Others

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:           

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube